Japan Considers Health Technology Assessments; Ponders Pharma Incentives
This article was originally published in PharmAsia News
Executive Summary
Japan’s Chuikyo is reviewing HTA systems in the UK, Germany, Australia and South Korea, but is also considering its own variation to reward industry compliance.
You may also be interested in...
Daiichi Sankyo's Edoxaban Enters Its First Market; Eisai "Very Pleased" With Eribulin Japanese Price Listing
TOKYO - Drugmakers introduced a number of new products in Japan this week, including the first launch globally of Daiichi Sankyo Co. Ltd.'s oral factor Xa inhibitor edoxaban, following the release of National Health Insurance price listings
FCPA In The China Framework Warrants Special Attention
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas Regains Japan Losses With Xtandi Expansion
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.